NCT03730038View on ClinicalTrials.gov

Effects of Pitavastatin Treatments on the Plasma Lgi3 Level in the Patients With Dyslipidemia

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 18, 2019

Primary Completion Date

February 13, 2020

Study Completion Date

February 13, 2020

Conditions
Dyslipidemias
Interventions
DRUG

Treatment of pitavastatin 4 mg qd for 12 weeks

Treatment of pitavastatin 4 mg qd for 12 weeks

BEHAVIORAL

Life-style modification

Nutritional support with the meal less than 65% of carbohydrate, less than 30% of fat. Exercise 3-4 times, 30 min

Trial Locations (1)

03722

Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT03730038 - Effects of Pitavastatin Treatments on the Plasma Lgi3 Level in the Patients With Dyslipidemia | Biotech Hunter | Biotech Hunter